Shawn Cross - Dec 9, 2025 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role
Chief Financial Officer
Signature
/s/ Kristen Williams, Attorney-in-Fact
Stock symbol
PCRX
Transactions as of
Dec 9, 2025
Transactions value $
-$215,501
Form type
4
Date filed
12/11/2025, 09:47 PM
Previous filing
Nov 13, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Cross Shawn Chief Financial Officer C/O PACIRA BIOSCIENCES, INC., 2000 SIERRA POINT PARKWAY, SUITE 900, BRISBANE /s/ Kristen Williams, Attorney-in-Fact 2025-12-11 0001734779

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCRX Common Stock Options Exercise $261K +15.9K +28.26% $16.45 72.1K Dec 9, 2025 Direct F1
transaction PCRX Common Stock Sale -$398K -15.9K -22.03% $25.03 56.3K Dec 9, 2025 Direct F1, F2
transaction PCRX Common Stock Options Exercise $150K +9.1K +16.18% $16.45 65.4K Dec 10, 2025 Direct F1
transaction PCRX Common Stock Sale -$229K -9.1K -13.93% $25.14 56.3K Dec 10, 2025 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCRX Stock Option (Right to Buy) Options Exercise $0 -15.9K -7.95% $0.00 184K Dec 9, 2025 Common Stock 15.9K $16.45 Direct F1, F4
transaction PCRX Stock Option (Right to Buy) Options Exercise $0 -9.1K -4.95% $0.00 175K Dec 10, 2025 Common Stock 9.1K $16.45 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.11, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 2 and 3.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.30, inclusive.
F4 The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.